The fourth batch of national mining rules online interpretation! The offer was held as scheduled on 3 February

January 25, the cause of the outbreak, the fourth batch of national organizations centralized procurement of drugs on-site training will be forced to cancel, but the joint procurement office did not "lost contract", as scheduled on-line release of port release documents to interpret the main points for the relevant enterprises to learn.
From this interpretation document, the fourth batch of national mining rules is relatively stable, in the shortlist rules slightly adjusted: the general rules and procedures are still first shortlisted elimination, and then the determination of the winning varieties; 70%; 4 and above 80%), only for Voliconazole oral normal release dosage form, nofluorosa star oral normal release dosage form, tebifen oral normal release dosage form, cephalosporine oral regular release dosage form and other 7 products in the above-mentioned basis correspondingly reduced by 10%.
need to focus on the fourth batch of countries in the entry rules with the previous three slightly adjusted: a maximum of 10 finalists are allowed, the corresponding number of actual declared enterprises can be 13 and above.
reporter compared the first three batches, the number of finalists was further relaxed, and in the unit can be compared price into the first finalist, from 6 enterprises to implement 6 into 4, 7 into 5, 8 into 6 ... Up to 10 finalists.
To the selection rules, there are still three conditions: 1, the price is not higher than the lowest price of 1.8 times;
the fourth batch of state mining will take place on February 3 as planned, according to the document.
8 heavy injections attracted attention although the above rules are mostly fine-tuned, but also caused high concern in the industry, especially injection varieties.
fourth batch of national mining involving a total of 45 products, 80 product regulations.
according to Minanet data, the total sales of purchased drugs in public hospital terminals in 2019 about 30 billion yuan, of which 11 drug sales of more than 1 billion yuan, accounting for about a quarter of the current round of procurement products.
combed the procurement list, in which Esso meprazole tablets, ammonia pills, ammonia bromosot injections, pyridamide tablets, ibuprofen injections, doso-tea-alkali injections and many other heavy-weight products are of particular concern.
not the first time that injections have been incorporated into national harvesting, but the concentration of these large clinical varieties is bound to lead to more speculation in the market.
the fourth batch of countries agreed to purchase the amount of about 17.3 billion yuan in the first year, dosso-tea-alkali, voliconazole, anti-torazole procurement amount is the top three.
from the Mienet data, the sample hospital sales used as a proton pump inhibitor for the treatment of excessive stomach acid-causing diseases reached 3 billion yuan in 2019.
first-line phlegm drug ammonia bromoso injectables in the same year the end of sales also reached 2.4 billion yuan.
" industry is more concerned, because with oral preparations, injection sales channels are basically in the hospital, the general out-of-hospital market sales ratio is very small, for injection drug companies, over-evaluation is a ticket, but no chance to collect is almost lost the entire market, that is, the loss of mrs.
the channel alone, the competition for injection collection will be more intense than for oral preparations.
industry predicts that injections or eye-catching points will be made when quoted next week.
statistics, although the growth rate of chemical injections slowed, but its market size is still rising year by year.
2019, the market size of end-drug injections in China's public medical institutions exceeded 630 billion yuan, an increase of about 20 billion yuan over 2018.
more and more large varieties of injections into the collection, the total size of the market will be further reduced, but the market will gradually differentiate.
is why attitudes among multinationals are changing: they should be more positive than in the first three.
Taking ammonia bromoso injections as an example, Mienet data show that in 2019 its original research enterprises occupied 23.56 percent of the market share of ammonia bromoso injections in Public Hospitals in China, but the number of generic drugs in China has exceeded ten, and no one is likely to be willing to give up this big market.
there are still many such products, in the fourth batch of national mining, Grigg Ingham, AZ, Pfizer and other enterprises in a number of varieties in the column.
addition, from the dosage form, in addition to oral normal release dosage form, injection and eye drops, slow release dosage form will also accelerate national extraction.
The first year of procurement amount of 1/3 varieties not more than 100 million from the procurement amount, there are careful industry people note that the first year of the fourth batch of procurement volume of about 17.3 billion yuan, if according to the first three batches of a total of four rounds of procurement scale from the reported to the average after the election of more than 70% of the experience estimated that the final procurement amount is estimated to be less than 5 billion yuan.
this is only an estimate, and everything is based on the final confirmed price accounting.
is worth playing with is that the fourth batch of national mining in the first year of procurement amount of less than 100 million yuan of varieties have 15, accounting for one-third of the total.
, especially for Guerrero oral regular release dosage form, sodium glass acid eye drops procurement amount is the lowest, are not more than 10 million yuan.
" rule allowing up to 10 picks resulted in more fragmentation and a sharp drop in purchases.
" industry analysis, with more and more products, can meet the full competitive conditions of the variety will be increasing, however, the number of finalists increased, on the surface can be shortlisted manufacturers increased, more competition is more moderate, more enterprises have food, but in fact, the procurement of the total plate unchanged, the available procurement share will be more differentiated, in fact, more intense competition.
Such as the first three varieties of this national harvest, dosso-tea base there are stone four drugs, Yangzijiang, Shanxi Nocheng Pharmaceuticals, Anhui Star Pharmaceuticals and other 5 enterprises to compete;
overall competitive landscape is more relaxed, but behind all kinds of killing machines, do not rule out the emergence of unpredictable circumstances.